Excitotoxicity contributes to epileptogenesis after severe traumatic brain injury (sTBI). Demographic and clinical risk factors for post-traumatic seizures (PTS) have been identified, but genetic risk remains largely unknown. Thus, we investigated whether genetic variation in astroglial glutamate transporter genes is associated with accelerated epileptogenesis and PTS risk after sTBI. Adults (n = 267) 18–75 years old were assessed over a three-year period post-TBI. Single nucleotide polymorphisms (SNPs) throughout the SLC1A2 and SLC1A3 genes were assayed. Kaplan-Meier estimates and log-rank statistics were used to compare seizure frequencies by genotype. Multivariate Cox proportional hazards regression was used to estimate hazard ratios (HRs) for genotypes significant in Kaplan-Meier analyses. Thirty-nine tagging SNPs were examined (SLC1A2: n = 21, SLC1A3: n = 18). PTS developed in 57 (21.4%) individuals. Of those with PTS, n = 20 (35.7%) had an immediate/early seizure within the first seven days, and n = 36 (64.3%) had a late seizure occurring between eight days and three years post-TBI. When adjusting for multiple comparisons, rs4869682 genotypes (SLC1A3, GG vs. T-carriers) were associated with time to first seizure (p = 0.003). Median time until first seizure was 20.4 days for individuals with a GG genotype and 44.8 days for T-carriers. After adjusting for covariates, rs4869682 GG-homozygotes had a 2.05 times increased PTS risk versus T-carriers (aHR = 2.08, 95% confidence interval: 1.20, 3.62, p = 0.009). Variation within SLC1A3 is associated with accelerated epileptogenesis and clinical PTS development after sTBI. Future studies should validate these findings and examine how genetic variation at rs4869682 may be a target for PTS prevention and treatment.
Get full access to this article
View all access options for this article.
References
1.
Harrison-FelixC., PretzC., HammondF.M., CuthbertJ.P., BellJ., CorriganJ., MillerA.C., and Haarbauer-KrupaJ. (2014). Life expectancy after inpatient rehabilitation for traumatic brain injury in the United States. J. Neurotrauma, 32, 1893–1901.
2.
Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation. (2015). Centers for Disease Control and Prevention: Atlanta.
3.
JuengstS.B., WagnerA.K., RitterA.C., SzaflarskiJ.P., WalkerW.C., ZafonteR.D., BrownA.W., HammondF.M., PughM.J., SheaT., KrellmanJ.W., BushnikT., and ArenthP.M. (2017). Post-traumatic epilepsy associations with mental health outcomes in the first two years after moderate to severe TBI: A TBI Model Systems analysis. Epilepsy Behav. 73, 240–246.
4.
DingK., GuptaP.K., and Diaz-ArrastiaR. (2016). Epilepsy after traumatic brain injury, in: LaskowitzD., and GrantG. (eds). Translational Research in Traumatic Brain Injury. CRC Press/Taylor and Francis Group: Boca Raton, FL.
5.
HuntR.F., BoychukJ.A., and SmithB.N. (2013). Neural circuit mechanisms of post–traumatic epilepsy. Front. Cell. Neurosci., 7, 89.
6.
RitterA.C., WagnerA.K., SzaflarskiJ.P., BrooksM.M., ZafonteR.D., PughM.J.V., FabioA., HammondF.M., DreerL.E., BushnikT., WalkerW.C., BrownA.W., Johnson-GreeneD., SheaT., KrellmanJ.W., and RosenthalJ.A. (2016). Prognostic models for predicting posttraumatic seizures during acute hospitalization, and at 1 and 2 years following traumatic brain injury. Epilepsia, 57, 1503–1514.
7.
DiamondM.L., RitterA.C., JacksonE.K., ConleyY.P., KochanekP.M., BoisonD., and WagnerA.K. (2015). Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development. Epilepsia, 56, 1198–1206.
8.
DiamondM.L., RitterA.C., FaillaM.D., BolesJ.A., ConleyY.P., KochanekP.M., and WagnerA.K. (2014). IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia, 55, 1109–1119.
9.
DarrahS.D., MillerM.A., RenD., HohN.Z., ScanlonJ.M., ConleyY.P., and WagnerA.K. (2013). Genetic variability in glutamic acid decarboxylase genes: associations with post-traumatic seizures after severe TBI. Epilepsy Res. 103, 180–194.
10.
RitterA.C., KammererC.M., BrooksM.M., ConleyY.P., and WagnerA.K. (2016). Genetic variation in neuronal glutamate transport genes and associations with posttraumatic seizure. Epilepsia, 57, 984–993.
11.
YamamotoT., RossiS., StiefelM., DoppenbergE., ZaunerA., BullockR., and MarmarouA. (1999). CSF and ECF Glutamate Concentrations in Head Injured Patients., in: Neuromonitoring in Brain Injury. Springer: Vienna, pps. 17–19.
12.
ZouH., BrayerS.W., HurwitzM., NiyonkuruC., FowlerL.E., and WagnerA.K. (2013). Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. Neurorehabil. Neural Repair, 27, 878–888.
13.
WilliamsS.M., SullivanR.K., ScottH.L., FinkelsteinD.I., ColditzP.B., LingwoodB.E., DoddP.R., and PowD.V. (2005). Glial glutamate transporter expression patterns in brains from multiple mammalian species. Glia, 49, 520–541.
14.
TanakaK., WataseK., ManabeT., YamadaK., WatanabeM., TakahashiK., IwamaH., NishikawaT., IchiharaN., KikuchiT., OkuyamaS., KawashimaN., HoriS., TakimotoM., and WadaK. (1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science, 276, 1699–1702.
15.
PetrG.T., SunY., FrederickN.M., ZhouY., DhamneS.C., HameedM.Q., MirandaC., BedoyaE.A., FischerK.D., ArmsenW., WangJ., DanboltN.C., RotenbergA., AokiC.J., and RosenbergP.A. (2015). Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci., 35, 5187–5201.
16.
JenJ.C., WanJ., PalosT.P., HowardB.D., and BalohR.W. (2005). Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology, 65, 529–534.
17.
CarneyN., TottenA.M., O'ReillyC., UllmanJ.S., HawrylukG.W.J., BellM.J., BrattonS.L., ChesnutR., HarrisO.A., KissoonN., RubianoA.M., ShutterL., TaskerR.C., VavilalaM.S., WilbergerJ., WrightD.W., and GhajarJ. (2017). Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery, 80, 6–15.
18.
BarrettJ.C., FryB., MallerJ., DalyM.J. (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263–265.
19.
LiJ., and JiL. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity, 95, 221–227.
20.
RothsteinJ.D., Dykes-HobergM., PardoC.A., BristolL.A., JinL., KunclR.W., KanaiY., HedigerM.A., WangY., SchielkeJ.P., and WeltyD.F. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron, 16, 675–686.
21.
van LandeghemF.K., WeissT., OehmichenM., and von DeimlingA. (2006). Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J. Neurotrauma, 23, 1518–1528.
22.
LehreK.P., LevyL.M., OttersenO.P., Storm-MathisenJ., and DanboltN.C. (1995). Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci., 15, 1835–1853.
23.
RobertsR.C., RocheJ.K., and McCullumsmithR.E. (2014). Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: A light and electron microscopic study. Neuroscience, 277, 522–540.
24.
BianchiM.G., BardelliD., ChiuM., and BussolatiO. (2014). Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease. Cell. Mol. Life Sci., 71, 2001–2015.
25.
van LandeghemF.K., StoverJ.F., BechmannI., BrückW., UnterbergA., BührerC., and von DeimlingA. (2001). Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia, 35, 167–179.
26.
RimaniolA.C., HaïkS., MartinM., Le GrandR., BoussinF.D., Dereuddre-BosquetN., GrasG., and DormontD. (2000). Na+ -dependent high-affinity glutamate transport in macrophages. J. Immunol., 164, 5430–5438.
27.
BeschornerR., DietzK., SchauerN., MittelbronnM., SchluesenerH.J., TrautmannK., MeyermannR., and SimonP. (2007). Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury. Histol. Histopathol., 22, 515–526.
28.
KirschnerM.A., ArrizaJ.L., CopelandN.G., GilbertD.J., JenkinsN.A., MagenisE., and AmaraS.G. (1994). The mouse and human excitatory amino acid transporter gene (EAAT1) maps to mouse chromosome 15 and a region of syntenic homology on human chromosome 5. Genomics, 22, 631–633.
29.
PetrovskiS., SzoekeC.E., SheffieldL.J., D'SouzaW., HugginsR.M., and O'BrienT.J. (2009). Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. Pharmacogenet. Genomics, 19, 147–152.
30.
ShazadiK., PetrovskiS., RotenA., MillerH., HugginsR.M., BrodieM.J., PirmohamedM., JohnsonM.R., MarsonA.G., O'BrienT.J., and SillsG.J. (2014). Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Res. 108, 1797–1805.
31.
MedinaA., BurkeS., ThompsonR.C., BunneyW.Jr., MyersR.M., SchatzbergA., AkilH., and WatsonS.J. (2013). Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder. J. Psychiatr. Res., 47, 1150–1156.
32.
SmithR.E., HaroutunianV., DavisK.L., and Meador-WoodruffJ.H. (2001). Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry, 158, 1393–1399.
33.
ScottH.L., PowD.V., Tannenberg, and DoddP.R. (2002). Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J. Neurosci. 22, RC206.
34.
AdamczykA., GauseC.D., SattlerR., VidenskyS., RothsteinJ.D., SingerH., and WangT. (2011). Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome. Psychiatr. Genet., 21, 90–97.
35.
HaugetoO., UllensvangK., LevyL.M., ChaudhryF.A., HonoréT., NielsenM., LehreK.P., and DanboltN.C. (1996). Brain glutamate transporter proteins form homomultimers. J. Biol. Chem., 271, 27715–27722.
36.
BrowningM., ShearD.A., BramlettH.M., DixonC.E., MondelloS., SchmidK.E., PoloyacS.M., DietrichW.D., HayesR.L., WangK.K., PovlishockJ.T., TortellaF.C., and KochanekP.M. (2016). Levetiracetam treatment in traumatic brain injury: operation brain trauma therapy. J. Neurotrauma, 33, 581–594.
37.
CaudleK.L., LuX.C., MountneyA., ShearD.A., and TortellaF.C. (2016). Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury. Restor. Neurol. Neurosci., 34, 257–270.
38.
ZouH., HurwitzM., FowlerL., and WagnerA.K. (2015). Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI. Brain Inj. 29, 78–85.
39.
LynchB.A., LambengN., NockaK., Kensel-HammesP., BajjaliehS.M., MatagneA., and FuksB. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A., 101, 9861–9866.
40.
LukyanetzE.A., ShkrylV.M., and KostyukP.G. (2002). Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 43, 9–18.
41.
KleinP., HerrD., PearlP.L., NataleJ., LevineZ., NogayC., SandovalF., TrzcinskiS., AtabakiS.M., TsuchidaT., van den AnkerJ., SoldinS.J., HeJ., and McCarterR. (2012). Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Arch. Neurol., 69, 1290–1295.
42.
FullerK.L., WangY.Y., CookM.J., MurphyM.A., and D'SouzaW.J. (2013). Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia, 54, 45–57.
43.
TekgülH., GencpinarP., ÇavuşoğluD., and DündarN.O. (2016). The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population. Seizure, 36, 16–21.
44.
HalmaE., de LouwA.J.A., KlinkenbergS., AldenkampA.P., IJffD.M., and MajoieM. (2014). Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure, 23, 685–691.
45.
VerrottiA., PreziosoG., Di SabatinoF., FrancoV., ChiarelliF., and ZaccaraG. (2015). The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure, 31, 49–55.
46.
Goldberg-SternH., FeldmanL., Eidlitz-MarkusT., KramerU., PerezS., PollakL., and Phatal-ValevskiA. (2013). Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram—a pilot study. Eur. J. Paediatr. Neurol., 17, 248–253.
47.
MbizvoG.K., DixonP., HuttonJ.L., and MarsonA.G. (2014). The adverse effects profile of levetiracetam in epilepsy: a more detailed look. Int. J. Neurosci., 124, 627–634.
48.
WagnerA.K., MillerM.A., ScanlonJ., RenD., KochanekP.M., and ConleyY.P. (2010). Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res. 90, 259–272.
49.
MyrgaJ.M., FaillaM.D., RickerJ.H., DixonC.E., ConleyY.P., ArenthP.M., and WagnerA.K. (2016). A dopamine pathway gene risk score for cognitive recovery following traumatic brain injury: methodological considerations, preliminary findings, and interactions with sex. J. Head Trauma Rehabil., 31, E15-29.
50.
FaillaM.D., MyrgaJ.M., RickerJ.H., DixonC.E., ConleyY.P., and WagnerA.K. (2015). Posttraumatic brain injury cognitive performance is moderated by variation within ANKK1 and DRD2 genes. J. Head Trauma Rehabil., 30, E54-E66.
51.
MyrgaJ.M., JuengstS.B., FaillaM.D., ConleyY.P., ArenthP.M., GraceA.A., and WagnerA.K. (2016). COMT and ANKK1 genetics interact with depression to influence behavior following severe TBI: an initial assessment. Neurorehabil. Neural Repair, 30, 920–930.
52.
WagnerA.K., ScanlonJ.M., BeckerC.R., RitterA.C., NiyonkuruC., DixonC.E., ConleyY.P., and PriceJ.C. (2014). The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI. J. Cereb. Blood Flow Metab., 34, 1328–1339.
53.
MartindaleJ.L., GoldsteinJ.N., and PallinD.J. (2011). Emergency department seizure epidemiology. Emerg. Med. Clin. North Am., 29, 15–27.
54.
NobleA.J., MarsonA.G., Tudur-SmithC., MorganM., HughesD.A., GoodacreS., and RidsdaleL. (2015). “Seizure First Aid Training” for people with epilepsy who attend emergency departments, and their family and friends: study protocol for intervention development and a pilot randomised controlled trial. BMJ Open, 5, e009040.
55.
RitterA.C., WagnerA.K., FabioA., PughM.J., WalkerW.C., SzaflarskiJ.P., ZafonteR.D., BrownA.W., HammondF.M., BushnikT., Johnson-GreeneD., SheaT., KrellmanJ.W., RosenthalJ.A., and DreerL.E. (2016). Incidence and risk factors of posttraumatic seizures following traumatic brain injury: A Traumatic Brain Injury Model Systems Study. Epilepsia, 57, 1968–1977.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
